Synpromics named among the top 50 fastest growing technology firms in the UK

Friday 16th November 2018, 10:30am

Synpromics, the leader in gene control, is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony.


Photo of Alexander Crawford and Michael Roberts - credit Deloitte

Deloitte technology fast 50

The Deloitte Technology Fast 50 is one of the UK's foremost technology award programmes. It is a ranking of the country's 50 fastest growing technology companies, based on revenue growth over the last four years. Now in its 21st successful year, it celebrates innovation and entrepreneurship.


Photo courtesy of Deloitte: Alexander Crawford (Calculus Capital Investment Director) and Michael Roberts (Synpromics CSO and Founder)



The Deloitte Technology Fast 50 is one of the UK's foremost technology award programmes. It is a ranking of the country's 50 fastest growing technology companies, based on revenue growth over the last four years. Now in its 21st successful year, it celebrates innovation and entrepreneurship.

Over the last three years Synpromics’ revenue has increased by over 2400%, with an accumulated deal value of over £300 million. This growth has been accompanied by a move to expanded facilities to accommodate additional staff and the opening of business development activities in the US. The Deloitte Fast 50 recognises this sustained growth and the ongoing development of Synpromics’ proprietary synthetic promoter technology. 

"We are thrilled to rank as one of the fastest growing technology companies in the UK. This recognises the team’s hard work in developing our technology and forming important and valuable partnerships across industry and academia. We look forward to continuing to grow, developing our technology to facilitate the production of gene therapies for a range of diseases."

Michael Roberts, CSO, Synpromics 

This accolade follows the recent announcement of positive pre-clinical data from uniQure, a key partner, using a liver-selective promoter developed by Synpromics. The data demonstrates that the promoter is at least eight times more potent than the current industry standard.


For further information, contact:

Corporate Contact:

David Venables
CEO Synpromics Ltd
T: +44 (0)131 651 9662
E: David.Venables@synpromics.com

PR Contact:

Deborah Cockerill / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: synpromics@sciad.com


Back to News